(3 minutes read)
HIV vaccine clinical trial has been prematurely halted in Uganda, Tanzania, and South Africa due to its lack of efficacy in preventing infection. The trial was part of the PrEPVacc initiative, which began in December 2020 and involved 1,512 healthy adults. It was expected to conclude in 2024, but an independent committee recommended its discontinuation since the vaccine’s efficacy could not be demonstrated.
HIV vaccine clinical trial has been prematurely halted in Uganda, Tanzania, and South Africa due to its lack of efficacy in preventing infection. The trial was part of the PrEPVacc initiative, which began in December 2020 and involved 1,512 healthy adults. It was expected to conclude in 2024, but an independent committee recommended its discontinuation since the vaccine’s efficacy could not be demonstrated.
The trial was testing two different vaccine combinations and a new form of oral pre-exposure prophylaxis. The majority of the participants were from high-risk infection populations. The failure of this trial, coupled with another in South Africa in 2020, highlights the difficulties of developing an effective HIV vaccine.
Read Also:
https://trendsnafrica.com/new-hiv-prevention-method-launched-in-south-africa/
https://trendsnafrica.com/hiv-aids-infection-rates-decline-but-still-prevalent-among-zambian-youth/
HIV is a virus that has caused around 40 million deaths worldwide, with a current living population of 39 million people. Although there are available treatments that control the virus and prevent the development of AIDS, an effective vaccine is considered a vital tool in eliminating AIDS as a public health threat.
